Search
for
Sort by
Community 30 of 937
- Phase 3 Study for PP405 officially posted
- Phoenix 2in1 reaction (min or fin)
- Phase 3 for PP405 will now start in 2027
- So why did the first pyrilutamide phase III fail?
- A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months.
- Experiencing Shedding on Phoenix 2in1 and Nizoral for 9 Months
- Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)
- Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
- I want to prepare a Topical Catalase with Phosphate Buffered Saline Solution.
- Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026
- TH07 by Triple Hair entering phase III trial
- Phase II topical dut study - outperforms oral fin with a minor DHT reduction
- Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
- 3 Months on “Phoenix” 2-in-1 pill (1mg fin + 3mg min oral)
- Breezula Phase 3 confusion - did they change something?
- Will Pelage include Norwood 7 hair loss in PP405 phase 3 trials to see its true regenerative potential?
- Shower thought: at least this might be the last year we don't have Phase 2 results.
- GT20029 Big Phase 2 Update Results!
- People are hyped about PP405 but what about Veradermics phase 2!
- Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
- Breezula phase 3 results where are youuuu👀
- Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!
- Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
- What is next for pp405 in phase 2b?
- Thoughts on new drug PP405? Already reached phase 2
- Breezula(CB)Phase3Results Date
- Kintor long term safety phase 3
- Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
- Update for PP405 - phase 2b underway
- KX826 New Phase 3 Trial In China for 2025: 1.0% concentration